SCHEMBL6850751

SCHEMBL6850751

O=Cc1sccc1-c1cnccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
KDM4E B2RXH2 2/20 0.34
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MAPK8 P45983 1/20 0.33
MAPK9 P45984 1/20 0.33
MAPK10 P53779 1/20 0.33
CYP1A2 P05177 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2A6 P11509 3/20 0.33
PIM2 Q9P1W9 1/20 0.32
HSD17B10 Q99714 1/20 0.32
PRKDC P78527 1/20 0.32
DCTPP1 Q9H773 1/20 0.32
TSHR P16473 1/20 0.31
KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6874568 0.84 ADORA2A (0.34) ADORA2AADORA1KDM4EHDAC1HDAC8
SCHEMBL6874558 0.84 ADORA2A (0.34) ADORA2AADORA1KDM4EHDAC1HDAC8
SCHEMBL6851800 0.81 ADORA2A (0.35) ADORA2AADORA1CYP1A2CYP2A6PIM2
SCHEMBL27645882 0.78 KDM4E (0.46) ADORA1KDM4ECYP1A2ALDH1A1CYP2A6
SCHEMBL6852750 0.77 ADORA2A (0.33) ADORA2AADORA1HDAC1HDAC8HDAC6
SCHEMBL6852062 0.77 ADORA2A (0.33) ADORA2AADORA1HDAC1HDAC8HDAC6
SCHEMBL6852065 0.77 ADORA2A (0.33) ADORA2AADORA1HDAC1HDAC8HDAC6
SCHEMBL6847827 0.77 MAPK8 (0.40) ADORA2AADORA1KDM4EHDAC1HDAC8
SCHEMBL6850776 0.75 CASP6 (0.33) ADORA2AADORA1KDM4EMAPK8MAPK9
SCHEMBL6850786 0.75 CASP6 (0.33) ADORA2AADORA1KDM4EMAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825170-B2 ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-11-30 US disclosed
EP-1453847-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS Ortho-Mcneil Pharmaceutical, Inc. (US) 2004-09-08 EP disclosed
US-20030220272-A1 6-O-acyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-27 US disclosed
WO-2003050132-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220272-A1 6-O-acyl ketolide antibacterials Q6ZSR9, ACSL6, RPS4Y1 ADORA2A 4680/4885ADORA1 4052/4885CCNC 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.